.png){kind=icon}
.png){kind=icon}
Return
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis
.png){kind=icon}
PRE
AI
N
M
H
C
M
A
M
B
N
A
J
S
A
D
T
C
J
S
DOI：10.1016/j.jtct.2026.06.008.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Prophylactic anakinra did not reduce grade ≥3 CAR T-associated neurotoxicity syndrome. • Prophylactic anakinra was associated with increased grade ≥3 infections. • No survival or response rate differences observed with anakinra prophylaxis. • Caution warranted for routine anakinra use.
Journal
IF:
4.4
Papers:
2.1K
Citations:
4.4K
Organization
Cited Papers